Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation Plc (PRTA) is a clinical-stage biotechnology company advancing novel antibody therapies for complex diseases involving protein misfolding. This news hub provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic partnerships shaping the company's trajectory in amyloidosis, neurodegenerative disorders, and inflammatory disease research.
Access authoritative reporting on PRTA's pipeline developments, including detailed coverage of Phase 1-3 trial outcomes, FDA interactions, and collaborative research initiatives. Our curated news collection enables stakeholders to track progress across therapeutic areas where Prothena specializes: targeting pathogenic proteins in Alzheimer's disease, Parkinson's disease, and rare amyloidosis conditions.
Key updates include earnings announcements, scientific conference presentations, intellectual property developments, and partnership expansions. Bookmark this page for structured access to press releases, peer-reviewed publication highlights, and expert analyses of Prothena's innovative immunotherapies.
Prothena Corporation plc (NASDAQ:PRTA), a clinical biotechnology firm, announced its participation in a fireside chat at the 2023 Bank of America Healthcare Conference in Las Vegas on May 9, 2023, at 9:20 AM PT. This event will showcase insights from the company’s senior management regarding their investigational therapeutics pipeline, focusing on protein dysregulation and neurodegenerative diseases. A live webcast of the chat will be available on Prothena's investor relations website, with a replay accessible for 90 days afterward. Prothena specializes in developing treatments for conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases, positioning itself as a key player in addressing these pressing health challenges.
Walgreens and Prothena have announced a collaboration to enhance patient recruitment for Prothena's PRX012, a potential Alzheimer’s treatment currently in the ASCENT-2 clinical trial. Walgreens will utilize its extensive network and healthcare capabilities to identify suitable candidates, focusing on underserved communities. This trial has received Fast Track designation from the FDA, indicating its potential significance in addressing Alzheimer’s disease, which affects over 6.5 million Americans aged 65 and older. The partnership aims to create a more diverse patient population for the trial, aligning with the ENACT Act to improve inclusivity in Alzheimer’s research. Key topline data from ongoing Phase 1 studies is expected by the end of 2023.
Prothena Corporation plc (NASDAQ:PRTA) unveiled new preclinical data for its anti-amyloid beta product candidate, PRX012, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases in Gothenburg, Sweden. The data indicates that PRX012 exhibits a 20-fold greater affinity for amyloid beta protofibrils compared to lecanemab and clears pyroglutamate-modified amyloid beta at lower concentrations than donanemab. These findings support PRX012's potential as a best-in-class treatment for Alzheimer’s disease, with implications for improved patient access and administration.
FAQ
What is the current stock price of Prothena (PRTA)?
What is the market cap of Prothena (PRTA)?
